Table 1.

Characteristics of patients treated with mobocertinib 160 mg/d

CharacteristicPatients with EGFRex20insa (n = 28)All patients (n = 136)
Age, median (range), y62 (28–84)62 (24–86)
Sex
 Female21 (75)90 (66)
 Male7 (25)46 (34)
Race
 White20 (71)103 (76)
 Asian5 (18)20 (15)
 Black1 (4)9 (7)
 Other or unknown2 (7)4 (3)
Histology
 Adenocarcinoma27 (96)128 (94)
 Squamous03 (2)
 Large cell1 (4)2 (1)
 Missing03 (2)
ECOG performance status
 06 (21)48 (35)
 122 (79)88 (65)
Number of prior systemic anticancer regimens
 0026 (19)
 14 (14)12 (9)
 29 (32)16 (12)
 ≥315 (54)29 (21)
 Unknown053 (39)
Type of prior systemic anticancer therapy
 Chemotherapy28 (100)54 (40)
 Prior checkpoint inhibitor therapy17 (61)32 (24)
 EGFR/HER2 TKI6 (21)26 (19)
History of smoking
 Never17 (61)83 (61)
 Former11 (39)51 (38)
 Current01 (1)
 Unknown01 (1)
Baseline CNS metastases12 (43)52 (38)
  • NOTE: Values are number (%) of patients, unless specified otherwise. Data cutoff: January 27, 2020.

  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aPatients who received 160 mg/d (initial dose) during dose escalation (n = 6) and in expansion cohort 1 (n = 22).